BD 2672234 - PowerLoc PAK Safety Infusion Set with Y-Injection Site, 22G x 0.75", 5/CS (Temp Sensitive; Non-Returnable) (Continental US Only)

BD 2672234 - PowerLoc PAK Safety Infusion Set with Y-Injection Site, 22G x 0.75", 5/CS (Temp Sensitive; Non-Returnable) (Continental US Only)

The BD 2672234 PowerLoc PAK Safety Infusion Set is a sterile, single-use port-access solution designed for accessing compatible surgically implanted vascular ports. The set features a 22-gauge non-coring needle with a 0.75-inch length and includes a Y-injection site for secondary access to the infusion pathway.

The PowerLoc system provides a fluid pathway for administering compatible medications and solutions, withdrawing blood specimens, flushing implanted ports, and delivering contrast media through appropriately rated power-injectable ports. The 22-gauge configuration provides a smaller needle profile for therapies and procedures that do not require the higher flow capability of a larger-gauge access needle.

The 0.75-inch needle length is designed for implanted ports positioned relatively close to the skin surface. Correct needle-length selection helps ensure secure septum access while supporting stable positioning, dressing application, and patient comfort.

The integrated Y-injection site provides an additional access point within the tubing for compatible medication administration, flushing, or connection of another approved fluid pathway. The set has an approximate priming volume of 0.4 mL, supporting efficient fluid-management planning during preparation and therapy.

An integrated safety mechanism is designed to help reduce accidental needlestick exposure during port deaccessing. Following needle removal, the safety design helps cover and secure the sharp needle before handling and disposal.

The PAK presentation provides an organized solution intended to simplify the multi-step sterile port-access preparation process. BD 2672234 is supplied five sets per case.

Key Benefits

• 22-gauge non-coring needle supports access to compatible implanted vascular ports.
• 0.75-inch needle length accommodates appropriately positioned superficial ports.
• Smaller 22-gauge profile may be suitable when moderate flow capability meets the requirements of the prescribed therapy.
• Power-injectable design supports compatible contrast-enhanced imaging procedures.
• Supports power-injection flow rates up to 2 mL per second when the complete access system is appropriately rated.
• Y-injection site provides secondary access for compatible medication, flushing, or fluid administration.
• Approximate 0.4 mL priming volume supports fluid-management planning.
• Non-coring needle design helps minimize unnecessary damage to the implanted port septum.
• Integrated safety mechanism helps protect the needle following port deaccessing.
• Safety design supports occupational needlestick-prevention practices.
• Compact port-access profile supports dressing application and ongoing site management.
• Suitable for compatible infusion therapy, blood sampling, port maintenance, and diagnostic imaging applications.
• PAK format helps organize essential supplies used during sterile port-access preparation.
• Five-per-case packaging supports controlled clinical inventory management.

Compatibility and Applications

The BD 2672234 PowerLoc PAK Safety Infusion Set is intended for use with compatible surgically implanted vascular access ports designed to accept non-coring port-access needles.

Potential applications include chemotherapy administration, antibiotic therapy, hydration, parenteral nutrition, long-term infusion therapy, blood specimen collection, implanted port flushing, and contrast-media delivery during compatible diagnostic imaging procedures.

The 22-gauge needle may be selected when a smaller needle profile and moderate flow capability are appropriate for the prescribed therapy. Selection should consider medication or solution viscosity, required flow rate, implanted port specifications, infusion-pump requirements, and professional clinical judgment.

The 0.75-inch length is generally suitable for implanted ports positioned relatively close to the skin surface. A needle that is too short may not completely access the port septum, while an unnecessarily long needle may affect stability, securement, and dressing placement.

The Y-injection site provides a secondary access point within the tubing. It may support compatible intermittent medication administration, flushing, or connection of another approved fluid pathway when permitted by the prescribed therapy and institutional protocol.

For power injection, the implanted port, access needle, tubing, connectors, Y-injection site, extension components, and every other component within the fluid pathway must be appropriately rated for the intended procedure. The lowest-rated component determines the maximum allowable operating pressure and flow rate.

Compatibility should be confirmed with the exact implanted port model, septum design, port depth, prescribed therapy, infusion pump, power injector, connector system, dressing materials, and institutional vascular-access procedures.

Usage Guidelines

The BD 2672234 should be used only by healthcare professionals trained and authorized to access implanted vascular ports. Current manufacturer instructions, aseptic technique, institutional procedures, and the implanted port manufacturer's directions should be followed throughout the procedure.

• Confirm the patient's identity, prescribed therapy, implanted port type, and power-injection status.
• Assess the location and depth of the implanted port before selecting the 0.75-inch needle.
• Verify that the 22-gauge configuration provides adequate flow capability for the intended procedure.
• Confirm that the Y-injection site configuration is appropriate for the planned clinical workflow.
• Inspect the sterile package for punctures, moisture, damage, contamination, or compromised integrity.
• Prepare the implanted port site according to institutional antisepsis and sterile-access procedures.
• Prime the primary tubing and any intended secondary fluid pathway completely with an approved solution.
• Remove air from the complete fluid pathway before accessing the implanted port.
• Stabilize the port and insert the non-coring needle perpendicular to the septum using an approved technique.
• Advance the needle carefully until appropriate contact with the base of the port reservoir is achieved.
• Verify correct placement according to facility policy, including aspiration for blood return when clinically appropriate.
• Flush the implanted port according to current manufacturer instructions and institutional protocol.
• Position and secure the tubing to reduce pulling, twisting, pressure, and dressing disruption.
• Apply an approved sterile dressing and maintain appropriate access-site visualization.
• Disinfect the Y-injection site before every access according to facility protocol.
• Maintain aseptic technique whenever connecting to or manipulating the Y-injection site.
• Monitor the site for pain, swelling, redness, leakage, displacement, or other complications.
• Confirm power-injection eligibility before connecting the system to a power injector.
• Do not exceed 2 mL per second or the lower operating limit of any connected component.
• After therapy, flush and lock the implanted port according to the prescribed protocol.
• Stabilize the port while withdrawing the needle and activating the safety mechanism.
• Confirm that the needle is fully secured in the protective position before handling.
• Dispose of the used device immediately in an approved sharps container.

Stop the procedure and assess the port-access system if resistance occurs during flushing, expected blood return cannot be obtained, the patient experiences unusual discomfort, or swelling, leakage, or another abnormality develops at the access site.

Certifications and Safety Standards

The BD 2672234 PowerLoc PAK Safety Infusion Set is intended for professional medical use within established vascular-access, infusion-therapy, diagnostic imaging, infection-prevention, and occupational safety programs.

The product is supplied for single use and should be handled according to established sterile technique. Package integrity should be verified before opening and the device should not be used if the sterile barrier has been compromised.

The integrated safety mechanism is designed to help protect the needle following removal from the implanted port. This feature supports occupational needlestick-prevention practices but does not replace appropriate clinician training, personal protective equipment, safe sharps handling, exposure-control procedures, or immediate disposal in an approved sharps container.

The non-coring needle is designed to access the septum of a compatible implanted vascular port while helping minimize unnecessary septum damage when used correctly. Needle gauge and length should be selected according to patient anatomy, implanted port depth, prescribed therapy, required flow rate, and current manufacturer instructions.

Healthcare organizations should review current manufacturer documentation for applicable FDA clearance, UDI information, sterilization method, shelf life, material composition, natural rubber latex status, DEHP information, maximum pressure, flow-rate specifications, and other technical or regulatory requirements.

Comparison with Competitors

Compared with conventional implanted port needles without integrated safety features, the BD PowerLoc system incorporates a protective mechanism designed to shield the needle following deaccessing. This can help reduce accidental needlestick exposure between needle removal and final sharps disposal.

Compared with infusion sets without a Y-injection site, BD 2672234 provides a secondary access point within the tubing. This may support compatible intermittent medication administration or additional fluid connections without disconnecting the primary infusion pathway.

Compared with non-power-injectable port-access sets, the PowerLoc platform supports compatible power-injection procedures when used with an approved power-injectable implanted port and within all specified pressure and flow limits.

Compared with 19-gauge and 20-gauge PowerLoc configurations, the 22-gauge needle provides a smaller external diameter but a lower maximum power-injection flow rate. Compatible 22-gauge configurations support up to 2 mL per second, while larger-gauge PowerLoc options may support higher flow requirements.

Compared with 1-inch and 1.5-inch access needles, the 0.75-inch configuration offers a lower profile for implanted ports positioned closer to the skin surface. Correct needle-length selection supports secure septum access, device stability, and effective dressing placement.

Compared with loose individual port-access supplies, the PAK presentation organizes essential procedural components within one package. This can help simplify preparation and support consistency across clinicians and treatment environments.

Alternative safety infusion sets may vary in gauge, needle length, safety mechanism, power-injection capability, Y-site design, priming volume, included components, and package quantity. BD 2672234 combines a 22-gauge, 0.75-inch non-coring needle with a Y-injection site, 0.4 mL priming volume, safety technology, and organized PAK presentation.

Typical User Profile and Application Scenarios

The BD 2672234 PowerLoc PAK Safety Infusion Set is intended for trained healthcare professionals responsible for accessing and managing implanted vascular ports. Typical users include infusion nurses, oncology nurses, radiology nurses, vascular-access specialists, physicians, advanced practice clinicians, and other qualified clinical personnel.

Common use environments include hospitals, oncology centers, outpatient infusion clinics, diagnostic imaging departments, ambulatory treatment centers, emergency departments, specialty practices, and other healthcare facilities where implanted vascular ports are routinely accessed.

The product may be selected for patients whose implanted port can be accessed appropriately with a 0.75-inch needle and whose prescribed therapy or diagnostic procedure is compatible with a 22-gauge device.

Typical application scenarios include medication infusion, antibiotic therapy, hydration, selected chemotherapy treatments, blood specimen collection, routine implanted port maintenance, and power injection of contrast media at compatible flow rates.

The Y-injection site is particularly useful in workflows requiring secondary access for compatible intermittent medication administration, flushing, or connection of another approved fluid pathway.

Best Practices for Use and Maintenance

The BD 2672234 is a sterile, single-use medical device and does not require maintenance as reusable equipment. Best practices focus on correct storage, product selection, sterile preparation, port-access technique, Y-site management, site monitoring, safety activation, and disposal.

• Store unopened sets under the environmental conditions specified by the manufacturer.
• Protect packages from moisture, excessive heat, freezing, crushing, punctures, and contamination.
• Rotate inventory according to expiration dates and facility stock-control procedures.
• Verify the BD 2672234 catalog number before opening the package.
• Confirm the 22-gauge size, 0.75-inch needle length, and presence of the Y-injection site.
• Assess the patient's tissue depth and implanted port position before selecting the needle length.
• Confirm that the required therapy and flow rate are appropriate for a 22-gauge device.
• Use strict aseptic technique during preparation, priming, insertion, connection, and dressing application.
• Prime all intended fluid pathways completely before accessing the implanted port.
• Stabilize the port during both needle insertion and removal.
• Position the tubing to avoid unnecessary pulling, twisting, or pressure at the access site.
• Scrub and disinfect the Y-injection site before every access according to institutional policy.
• Keep unused access points capped and protected from contamination.
• Monitor the port site and tubing connections throughout therapy.
• Verify the power-injectable status of the complete system before a powered procedure.
• Never exceed the lowest pressure or flow-rate limit of any connected component.
• Do not bend, cut, modify, repair, or otherwise alter the infusion set.
• Do not reuse, clean, resterilize, or reprocess the single-use device.
• Confirm complete safety activation immediately after needle withdrawal.
• Place the protected device directly into an approved sharps container.

Regulatory and Safety Information

The BD 2672234 PowerLoc PAK Safety Infusion Set should be used only by appropriately trained healthcare professionals and only for applications consistent with current manufacturer labeling, implanted port instructions, professional clinical judgment, and institutional policy.

Before use, verify the product identity, 22-gauge size, 0.75-inch needle length, Y-injection site configuration, sterile package integrity, expiration date, and compatibility with the implanted vascular port. Do not use a device that is expired, damaged, contaminated, or supplied in compromised packaging.

The set should not be used for power injection unless the implanted port and every connected component are specifically rated for power injection. The permitted pressure, flow rate, contrast-media viscosity, and other operating conditions must be confirmed before beginning the procedure.

Compatible 22-gauge PowerLoc configurations support power-injection flow rates up to 2 mL per second when used under manufacturer-specified conditions. The lowest-rated component within the complete system determines the maximum allowable operating limit.

Incorrect needle-length selection, incomplete septum access, excessive pressure, needle displacement, or improper securement may cause infiltration, extravasation, tissue injury, leakage, implanted port damage, interrupted therapy, or other complications.

The Y-injection site should be accessed only with compatible devices using appropriate disinfection and aseptic technique. Improper manipulation or inadequate disinfection may increase the risk of contamination, connection failure, or bloodstream infection.

The integrated safety mechanism should be activated according to current manufacturer instructions. The used device remains a contaminated sharp following deaccessing and must be discarded immediately in an approved sharps container.

The product is supplied five sets per case and is listed as temperature sensitive and non-returnable. Purchasing personnel should confirm current availability, shipping eligibility, storage requirements, order quantity, and applicable return conditions before purchasing.

How to Order

Select the BD 2672234 - PowerLoc PAK Safety Infusion Set with Y-Injection Site, 22G x 0.75" and add it to your cart. Complete checkout with your preferred shipping and payment options. For bulk orders, quotes, or further assistance, contact CIA Medical customer service at (312)275-5850 or use the contact form on this page.